Letter: immunogenicity is not the root cause for loss of response to anti-TNF agents in patients with IBD in TDM era

被引：4
作者：
Alsoud, Dahham [1 ]
Verstockt, Bram [1 ,2 ]
Vermeire, Severine [1 ,2 ]
机构：
[1] Katholieke Univ Leuven, Dept Chron Dis Metab & Ageing, Translat Res Gastrointestinal Disorders TARGID IB, Leuven, Belgium
[2] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2022年 / 55卷 / 07期
关键词：
D O I：
10.1111/apt.16797
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：885 / 886
页数：2
相关论文
共 9 条
  • [1] Breaking the therapeutic ceiling in drug development in ulcerative colitis
    Alsoud, Dahham
    Verstockt, Bram
    Fiocchi, Claudio
    Vermeire, Severine
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (07): : S89 - S95
  • [2] Supratherapeutic Infliximab Levels Do Not Predict Risk of Short-term Complications in Adults With Crohn's Disease
    Bhattacharya, Abhik
    Travis, Daniel
    Osterman, Mark T.
    Lewis, James D.
    Rao, Bhavana Bhagya
    Lee, Helen
    Lichtenstein, Gary R.
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 2023, 57 (01) : 66 - 73
  • [3] A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease
    Billiet, Thomas
    Dreesen, Erwin
    Cleynen, Isabelle
    Wollants, Willem-Jan
    Ferrante, Marc
    Van Assche, Gert
    Gils, Ann
    Vermeire, Severine
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 (10) : 1438 - 1445
  • [4] Immunogenicity to infliximab is associated with HLA-DRB1
    Billiet, Thomas
    Vande Casteele, Niels
    Van Stappen, Thomas
    Princen, Fred
    Singh, Sharat
    Gils, Ann
    Ferrante, Marc
    Van Assche, Gert
    Cleynen, Isabelle
    Vermeire, Severine
    [J]. GUT, 2015, 64 (08) : 1344 - U196
  • [5] Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease
    Colman, Ruben J.
    Xiong, Ye
    Mizuno, Tomoyuki
    Hyams, Jeffrey S.
    Noe, Joshua D.
    Boyle, Brendan
    D'Haens, Geert R.
    van Limbergen, Johan
    Chun, Kelly
    Yang, Jane
    Rosen, Michael J.
    Denson, Lee A.
    Vinks, Alexander A.
    Minar, Phillip
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (05) : 593 - 603
  • [6] Dashboard-Driven Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces Immunogenicity
    Dubinsky, Marla C.
    Mendiolaza, Michelle L.
    Phan, Becky L.
    Moran, Hunter R.
    Tse, Stacy S.
    Mould, Diane R.
    [J]. INFLAMMATORY BOWEL DISEASES, 2022, 28 (09) : 1375 - 1385
  • [7] HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease
    Sazonovs, Aleksejs
    Kennedy, Nicholas A.
    Moutsianas, Loukas
    Heap, Graham A.
    Rice, Daniel L.
    Reppell, Mark
    Bewshea, Claire M.
    Chanchlani, Neil
    Walker, Gareth J.
    Perry, Mandy H.
    McDonald, Timothy J.
    Lees, Charlie W.
    Cummings, J. R. Fraser
    Parkes, Miles
    Mansfield, John C.
    Irving, Peter M.
    Barrett, Jeffrey C.
    McGovern, Dermot
    Goodhand, James R.
    Anderson, Carl A.
    Ahmad, Tariq
    [J]. GASTROENTEROLOGY, 2020, 158 (01) : 189 - 199
  • [8] Loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease
    Schultheiss, Johannes P. D.
    Mahmoud, Remi
    Louwers, Jonas M.
    van der Kaaij, Michiel T.
    van Hellemondt, Boris P.
    van Boeckel, Petra G.
    Mahmmod, Nofel
    Jharap, Bindia
    Fidder, Herma H.
    Oldenburg, Bas
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (10) : 1298 - 1308
  • [9] How Do We Predict a Patient's Disease Course and Whether They Will Respond to Specific Treatments?
    Verstockt, Bram
    Parkes, Miles
    Lee, James C.
    [J]. GASTROENTEROLOGY, 2022, 162 (05) : 1383 - 1395
1